Silexion Therapeutics: Funding, Investors & Team (Sep 2026)
Silexion Therapeutics is a biotechnology company that focuses on developing treatments for KRAS-driven cancers. The company's lead product, SIL-204, is a small interfering RNA (siRNA) therapy in an extended-release formulation for the treatment of locally advanced pancreatic cancer. Silexion offers its clinical-stage oncology platform with plans for further trials to improve treatment outcomes for patients with specific KRAS mutations.
Silexion Therapeutics has raised $1.0M across 1 funding round on record, the most recent an undisclosed round of $1.0M announced in May 2026.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Silexion Therapeutics Company Profile and Key Stats
Latest funding round on record: May 2026.
Silexion Therapeutics Funding Rounds
Silexion Therapeutics Founders and Leadership Team
Contact details for the Silexion Therapeutics team: 1 has a LinkedIn profile.
Start 14-day free trial →Silexion Therapeutics Funding Compared to Other Biotechnology Startups
Silexion Therapeutics' latest round of $1.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Silexion Therapeutics in Biotechnology and Illinois City
Companies Similar to Silexion Therapeutics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Silexion Therapeutics Funding FAQs
What does Silexion Therapeutics do?
Silexion Therapeutics is a biotechnology company that focuses on developing treatments for KRAS-driven cancers. The company's lead product, SIL-204, is a small interfering RNA (siRNA) therapy in an extended-release formulation for the treatment of locally advanced pancreatic cancer. Silexion offers its clinical-stage oncology platform with plans for further trials to improve treatment outcomes for patients with specific KRAS mutations.
How much funding has Silexion Therapeutics raised?
Silexion Therapeutics has raised $1.0M across 1 round on record. The most recent is an undisclosed round of $1.0M announced in May 2026.
When did Silexion Therapeutics last raise funding?
Silexion Therapeutics' most recent funding round on record is an undisclosed round of $1.0M, announced in May 2026.
Who founded Silexion Therapeutics?
FundedIQ lists Ilan Hadar (Founder) at Silexion Therapeutics.
Where is Silexion Therapeutics headquartered?
Silexion Therapeutics is based in Illinois City, Illinois, United States.
How many employees does Silexion Therapeutics have?
Silexion Therapeutics is in the 11-50 employee band.
How does Silexion Therapeutics' funding compare to other Biotechnology startups?
Silexion Therapeutics' latest round of $1.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Silexion Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Silexion Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.